Tracked deals
6
6 tracked deals across 2021-2026.
Public Company
Healthcare
Johnson & Johnson
New Brunswick, New Jersey, United States
At Johnson & Johnson, we believe health is everything. Our strength in healthcare innovation empowers us to build a world where complex diseases are prevented, treated, and cured, where treatments are smarter and less invasive, and solutions are personal. Through our expertise in Innovative Medicine and MedTech, we innovate across the full spectrum of healthcare solutions.
- Focus Areas
- Innovative Medicine, MedTech, Oncology therapeutics
- Website
- www.jnj.com
Recent pace
5
5 tracked deals announced in the last 12 months.
Deal mix
Buyout
5 buyout · 1 growth capital
Johnson & Johnson Acquisition Volume by Year
Last 3 years
Actual
Full-year estimate
Supporting Data
Recent Transactions
-
- Buyer
- Johnson & Johnson
- Target
- Sail Biomedicines
- Industry
- Biotechnology
- Location
- United States
- Type
- Growth capital
Johnson & Johnson entered into strategic agreements with Sail Biomedicines to collaborate on in vivo CAR-T therapies and secured an exclusive option to acquire Sail for $2.58 billion. The deal includes initial payments totaling $785 million (including a $465 million equity investment) and up to $140 million in additional development milestone payments, with the $2.58 billion payable if the option is exercised.
-
- Buyer
- Johnson & Johnson
- Target
- Firefly Bio, Inc.
- Industry
- Biotechnology
- Location
- California, United States
- Type
- Buyout
Johnson & Johnson entered into a definitive agreement to acquire Firefly Bio, Inc. for $1 billion in cash. The deal is intended to expand Johnson & Johnson’s oncology pipeline using Firefly Bio’s proprietary Firelink degrader antibody conjugate platform, including preclinical candidates for KRAS-driven and other hard-to-treat solid tumors.
-
May 28, 2026
- Buyer
- Johnson & Johnson
- Target
- Atraverse Medical
- Industry
- Medical Devices
- Location
- California, United States
- Type
- Buyout
Johnson & Johnson acquired Atraverse Medical, strengthening its J&J MedTech cardiac electrophysiology portfolio. The acquisition follows the May 15, 2026 close and is referenced in connection with medtech founder John Slump’s subsequent launch of Metis MedTech.
-
April 26, 2026
- Buyer
- Johnson & Johnson
- Target
- Atraverse Medical, Inc.
- Industry
- Medical Devices
- Location
- California, United States
- Type
- Buyout
Johnson & Johnson entered into a definitive agreement to acquire Atraverse Medical, a privately held medtech company developing the HOTWIRE Transseptal Access System for left-heart access during cardiac electrophysiology procedures. The deal is expected to close in Q2 2026, subject to customary closing conditions, with financial terms not disclosed.
-
- Buyer
- Johnson & Johnson
- Target
- Halda Therapeutics OpCo, Inc.
- Industry
- Healthcare Services
- Location
- United States
- Type
- Buyout
Johnson & Johnson completed its acquisition of Halda Therapeutics OpCo, Inc. for $3.05 billion in cash. The deal brings Halda’s proprietary RIPTAC platform and its clinical-stage prostate cancer therapy HLD-0915, along with earlier-stage RIPTAC candidates for other solid tumors, into J&J’s oncology portfolio.
-
- Buyer
- Datavant, New Mountain Capital, Sixth Street, Goldman Sachs Asset Management, Roivant Sciences, Transformation Capital, Merck Global Health Innovation Fund, Labcorp, Cigna Ventures, Johnson & Johnson Innovation – JJDC, Inc., Flex Capital
- Target
- Ciox Health
- Industry
- Data & Analytics
- Location
- Georgia, United States
- Type
- Buyout
Datavant and Ciox Health signed a definitive agreement to merge in a transaction valued at $7.0 billion, creating a combined company to be named Datavant that will be the largest neutral health data ecosystem in the United States. The deal is supported by an investor group led by New Mountain Capital with significant new investment from Sixth Street and participation from Goldman Sachs Asset Management, Roivant Sciences and other strategic and financial investors; upon closing Pete McCabe will be CEO and Travis May will be President.
Related Acquisition Pages
Biotechnology Buyers & Acquisitions
2 tracked deals by Johnson & Johnson.
Medical Devices Buyers & Acquisitions
2 tracked deals by Johnson & Johnson.
Data & Analytics Buyers & Acquisitions
1 tracked deal by Johnson & Johnson.
Healthcare Services Buyers & Acquisitions
1 tracked deal by Johnson & Johnson.
Acquisitions in California
3 tracked deals by Johnson & Johnson.
Acquisitions in Georgia
1 tracked deal by Johnson & Johnson.
Selling a company? Get in front of buyers like Johnson & Johnson
Turn tracked acquisition activity into an outreach-ready buyer list.